GLP1减重宝典·2025-05-13 15:13Core Viewpoint - The SURMOUNT-5 study demonstrates that Tirzepatide significantly outperforms Semaglutide in weight loss and waist circumference reduction among overweight adults with obesity-related comorbidities but without diabetes [2][4]. Summary by Sections Study Results - Tirzepatide achieved an average weight loss of 20.2% compared to Semaglutide's 13.7% over 72 weeks, with a relative weight loss effect of 1.47 times greater than Semaglutide [2][3]. - Participants in the Tirzepatide group lost an average of 22.8 kg, while those in the Semaglutide group lost 15.0 kg [2]. - In key secondary endpoints, 64.6% of Tirzepatide participants lost at least 15% of their body weight, compared to 40.1% for Semaglutide [3]. Expert Commentary - Dr. Louis J. Aronne highlighted the significant weight loss effects of Tirzepatide, reinforcing its position as an effective option for obesity management [4]. - Dr. Leonard C. Glass emphasized the leading role of Tirzepatide in obesity treatment, providing valuable guidance for clinicians [4]. - Derrick Hirsh pointed out the public health implications of obesity in China, noting that obesity-related healthcare spending is expected to account for about 22% of total healthcare expenditures by 2030 [4]. Safety and Mechanism - The overall safety profile of Tirzepatide was consistent with previous studies, with gastrointestinal issues being the most common adverse events [6]. - Tirzepatide activates both GIP and GLP-1 receptors, giving it a natural advantage over Semaglutide, which only targets GLP-1 receptors [6]. Market Competition - Both Tirzepatide and Semaglutide face production bottlenecks, prompting expansions in manufacturing capacity by both companies [7]. - In Q1 2025, Semaglutide's weight loss version generated approximately $2.448 billion in revenue, while Tirzepatide generated about $2.31 billion, with Tirzepatide's sales growing at a faster rate [7]. - Novo Nordisk and Eli Lilly are competing in the oral weight loss drug market, with Eli Lilly planning to submit its oral GLP-1 drug Orforglipron for regulatory approval by the end of 2025 [7].